Led · Seed · Dec 2025

Founded in 2023 by Joel Uussaari and Aleksi Kaistinen, Freepress uses an AI “virtual news editor” to analyse hundreds of thousands of publicly available and licensed articles from multiple countries and generate key information in the user’s language. The consumer-facing product delivers real-time notifications on selected topics and allows users to follow international news without manual searching. Freepress offers its AI-generated summaries free of charge and complements them with full-length articles from partner publishers, sharing up to 50 % of its revenue from both consumer and business users with those publishers. To grow its audience, the company plans to add new languages and enter additional markets through collaborations with local publishers. Future roadmap items include business-oriented tools for content use, media monitoring, and market-behaviour forecasting. The company has not disclosed revenue or user metrics but is financing these initiatives with newly raised seed capital. Although founded in 2023, the service is reported to have launched in Finland in autumn 2025 according to the company’s announcement.

Participated · Equity · Nov 2025

Cronvall is a Finnish technology company focused on modernising industrial and construction procurement through a single cloud platform that connects buyers with more than 150 vetted suppliers. Its software lets firms compare real-time prices, place orders, and track deliveries, bringing new transparency and efficiency to traditionally fragmented supply chains. The service is already used by over 8,000 industrial and construction customers, ranging from SMEs to publicly listed enterprises. Cronvall reports that it is on track to surpass €6 million in annual turnover, buoyed by revenue in Germany that has grown more than fivefold over the past year. The platform’s data features also help clients address tightening EU sustainability and reporting requirements, such as the Corporate Sustainability Reporting Directive. With the fresh capital, the company intends to deepen its presence in Germany, expand across Europe, and continue enhancing its technology to deliver both cost efficiency and measurable CO₂ reductions. Cronvall ultimately aims to build the leading European network for industrial procurement.

Led · Series B · May 2025

TILT Biotherapeutics specialises in oncolytic adenovirus therapies using its proprietary TILT® platform to deliver immune-activating cytokines (TNF alpha and IL-2) to tumours. Its lead candidate, TILT-123 (igrelimogene litadenorepvec), is a chimeric oncolytic adenovirus administered intratumorally or intravenously designed to convert immunologically “cold” tumours into “hot” tumours and potentiate T-cell therapies and checkpoint inhibitors. The company is running multiple clinical trials, including Phase 2 planning for platinum-resistant ovarian cancer and Phase 1b studies in melanoma; interim Phase 1b results are expected in H2 2026. TILT reported Phase 1a (PROTA) data showing disease control in 64% of evaluable patients (9/14), a 20% overall response rate at the highest dose level, median progression-free survival of 98 days, and overall survival of 190 days. The company has established collaborations with Merck & Co. (MSD) and Merck KGaA and has opened its first U.S. site with plans to add several more in 2025. With a $25.6M Series B, TILT intends to accelerate TILT-123 development and expand its U.S. clinical presence. TILT Biotherapeutics develops cancer immunotherapies based on proprietary armed oncolytic adenoviruses that deliver cytokines and other molecules to modify the tumor microenvironment and enhance T‑cell activity. Its lead asset, TILT-123, is a 5/3 chimeric adenovirus armed with TNF‑alpha and IL‑2 and is currently in Phase I clinical trials. The company positions its platform to work synergistically with immune checkpoint inhibitors, TIL therapy, and CAR‑T approaches. TILT has active clinical collaborations with Merck KGaA and Pfizer (avelumab) and with MSD (pembrolizumab) across several indications, and a development/commercialization partnership in Greater China with Biotheus. The company plans to use new funding to advance combination trials into Phase II. TILT is based in Helsinki with an office in Boston and was established in 2013 as a University of Helsinki spin‑out. TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on proprietary oncolytic adenoviruses armed with molecules such as cytokines to modulate T-cell responses. Its lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with human TNF alpha and IL-2, which has shown a 100% response rate in preclinical in vivo models and is currently in Phase 1 clinical trials. The company is progressing multiple clinical trials in Europe and the US and is partnering with Merck KGaA and Pfizer to study TILT-123 with the PD-L1 inhibitor Avelumab and with MSD to investigate combination therapy with Pembrolizumab. TILT plans to advance Phase I/II programs using TILT-123 plus immune checkpoint inhibitors across indications including ovarian, head and neck, and lung cancers. Founded in 2013 and based in Helsinki, Finland, TILT has prior support from Lifeline Ventures, Tesi, angel investors, Business Finland, and the European Innovation Council. The company recently completed the first close of a financing round and appointed Dr. Tuija Keinonen as Chair of the Board to support its expanding clinical footprint. Tilt Biotherapeutics is a clinical-stage biotechnology company and 2013 spin-out from the University of Helsinki developing cytokine-armed oncolytic adenoviruses to enhance T-cell therapies. Its lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines (TNF alpha and IL-2). TILT-123 has completed GLP preclinical studies and CMC for Phase 1 studies and is being developed for solid tumors as monotherapy or in combination with TILs or checkpoint inhibitors. The company intends to use the new funding to advance TILT-123 into Phase 1 trials in Europe and the United States and to prepare for Phase 2. Tilt is also investing in an innovative production process to scale up GMP manufacturing. Partnerships include a collaboration with Biotheus for Greater China rights and a collaboration with Merck KGaA and Pfizer to investigate TILT-123 with the PD-L1 inhibitor Avelumab. The company is led by CEO Akseli Hemminki. TILT Biotherapeutics develops oncolytic viruses designed to enhance tumor T‑cell therapies, including TIL, CAR‑T and checkpoint inhibitors. Its lead candidate, TILT‑123, is a TNFα/IL2‑armed oncolytic adenovirus currently in preclinical development with GMP production ongoing. The company plans first Phase I clinical trials in early 2018, including a trial in two European centers addressing metastatic melanoma in combination with TILs. TILT highlights that its virus backbone has shown safety in humans and can access distant metastases via the vasculature. The platform has been engineered for improved efficacy and safety in cancer cells, and the founding team has published extensively and treated patients with oncolytic viruses. TILT is pursuing additional capital and collaborations with companies working on checkpoint inhibitors and CAR‑T technologies.

Participated · Equity · Feb 2025

StemSight develops advanced stem cell therapies using induced pluripotent stem (iPS) cell technology to manufacture corneal cells at scale and combine them with biomaterials for off-the-shelf treatments. Its lead program targets limbal stem cell deficiency (LSCD), a rare but severe form of corneal blindness; StemSight cites ~23k LSCD patients in Europe and the U.S. and notes global corneal blindness affects over 12 million people. The company positions its donor-independent, one-time cell therapy as a scalable, consistent alternative to traditional donor-dependent solutions. StemSight raised €2.3 million to fund key preclinical studies, expand R&D, and run manufacturing pilots to advance toward clinical trials. The team, founded in 2021 by Heli Skottman and Laura Koivusalo, plans to expand its pipeline to additional ocular diseases and address the global shortage of donor corneas. StemSight is developing an off-the-shelf human stem cell therapy intended to cure severe corneal blindness without relying on donor cornea tissue. The company aims to help millions affected by corneal blindness, citing roughly 12.7 million people worldwide waiting for corneal transplants and around 300 new fully untreatable cases per year in the EU. The €500,000 seed funding will be used to support clinical trials and market approval of their treatment. The team spun out of a Tampere University research group and has worked on the innovation for a combined 30 years. Founders hold PhDs in Biotechnology, Genetics, and Cell and Tissue Engineering, and the company is noted as one of the few all-female teams in the Nordic deep tech scene.

Participated · Seed · Jun 2024

Flow Computing develops a companion Parallel Processing Unit (PPU) chip that sits alongside a CPU to orchestrate nanosecond-scale task movement, aiming to turn serial CPU execution into a more parallelized flow. The company says the PPU can double CPU performance instantly and—with refactoring or recompilation—yield increases up to 100x on some workloads. Flow has demonstrated the technology in FPGA-based test setups and is developing recompilation tools to help software makers optimize for PPU-enabled designs. The PPU must be integrated at the chip-design level, so the first commercial parts will require chipmaker adoption rather than retroactive deployment. Flow is a spinout of Finland’s state-backed research organization VTT; the IP is owned by Flow. The company emerged from stealth after raising €4 million in pre-seed funding.